Sundrug Co., Ltd. — Cyborg Score 6/10

Strategic Profile

Sundrug maintains a dual-segment model: its Drug Store Business focuses on pharmaceutical products, cosmetics, and daily necessities, while its Discount Store Business offers food and household goods. The company leverages a widespread physical retail network to provide convenient consumer access and operates with stable profitability, though recent share price performance has lagged earnings growth.

Cyborg Score Rationale

Sundrug demonstrates stable fundamentals with consistent earnings growth (1% annualized over 3 years), a strong balance sheet, and reliable dividend payments. However, share price underperformance relative to earnings, mixed valuation metrics relative to peers, and governance concerns (lack of independent directors) temper the outlook.

Top Insights

• Drug store segment is primary revenue driver at ¥459.6B, up from ¥437.95B year-prior, showing modest organic growth
• Market cap of ¥495B with low volatility (2.16%) suggests investor perception of defensive, stable business model
• Dividend yield of 3.09% in 2024 with 49.45% payout ratio indicates established dividend aristocrat status
• Share price underperformance (-7% annually over 3 years) despite earnings growth signals market skepticism toward growth prospects

Named Competitors

• Pharmacy Chain — Major Japanese pharmacy chain operator
• Pharmacy Retailer — Large-scale pharmacy and general merchandise retailer
• Discount Store Operator — Discount store and pharmacy operator in Japan

Recent Developments

• (Oct 2025) Employee count reached 7,140 employees as company continues stable operations
• (2024) Dividend yield improved to 3.09% with sustainable 49.45% payout ratio
• (2025) Market capitalization stabilized around ¥495 billion with modest week-on-week growth of 0.53%

Open the full interactive Sundrug Co., Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.